Randomized Trialhigh evidence
Half-dose rivaroxaban vs antiplatelet therapy for preventing silent cerebral embolism after left atrial appendage occlusion: the HALO-SCE trial.
European heart journal·August 31, 2026·PMID 42670954
Why it mattersOptimal antithrombotic therapy after LAAO remains uncertain, and silent cerebral embolism may contribute to cognitive decline. This trial provides randomized evidence that low-dose rivaroxaban reduces subclinical brain injury and cognitive deterioration compared with antiplatelet therapy, informing post-procedure management in eligible patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled